Abstract
Objective To determine whether SLE patients with inflammatory joint symptoms and ultrasound-synovitis achieve better clinical responses to glucocorticoid compared to patients with normal scans. Secondary objectives included identification of clinical features predicting ultrasound-synovitis.
Methods A longitudinal muticentre study of SLE patients with physician-diagnosed inflammatory joint pain was undertaken. Clinical assessments, patient-reported outcomes, and bilateral hands and wrist ultrasound were collected at 0-, 2- and 6-weeks after intramuscular methylprednisolone 120mg. The primary outcome (determined via internal pilot analysis) was EMS-VAS at 2-weeks, adjusted for the baseline value, comparing patients with positive (GS≥2 and/or PD≥1) and negative ultrasound. Post-hoc analyses adjusting for fibromyalgia were performed.
Results Of 133 patients recruited, 78/133 had positive ultrasound, but only 68% of these had ≥1 swollen joint. Of 66/133 patients with ≥1 swollen joint, 20% had negative ultrasound. Positive ultrasound was associated with joint swelling, symmetrical small joint distribution and serology. In full analysis set (n=133) there was no difference in baseline-adjusted EMS-VAS at week 2 (−7.7mm 95% CI − 19.0mm, 3.5mm, p=0.178). After excluding 32 fibromyalgia patients, response was significantly better in patients with positive ultrasound at baseline (baseline-adjusted EMS-VAS at 2-weeks - 12.1 mm, 95% CI −22.2mm, −0.1mm, p=0.049). This difference was greater when adjusted for treatment (−12.8mm (95% CI −22mm, −3mm), p=0.007). BILAG and SLEDAI responses were higher in ultrasound-positive patients.
Conclusions In SLE patients without fibromyalgia, those with positive ultrasound had a better clinical response to therapy. Imaging-detected synovitis should be used to select SLE patients for therapy and enrich clinical trials.
Competing Interest Statement
Dr Vital has received grants from AstraZeneca and Sandoz. He has received honoraria from AstraZeneca, GSK, Roche and Aurinia.
Funding Statement
This research was supported by a grant from LupusUK and the National Institute of Health Research (CS-2013-13-032).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
North West - Greater Manchester Central Research Ethics Committee 16/NW/0060
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosures This work was funded by a grant from LupusUK and supported by a clinician scientist fellowship from the NIHR for Dr Vital. Coziana Ciurtin has received a research grant from Pfizer and personal fees from Roche and Modern Bioscience. Chris Edwards has received personal fees from GSK, BMS and Roche. David Isenberg has received personal fees paid to a charity from Merck Serono, AstraZeneca, Celgene, Eli Lilly and Servier. Philip Conaghan has received personal fees from AbbVie, AstraZeneca, BMS, Galapagos, Gilead, Janssen, Novartis and Pfizer. Paul Emery has received research grants paid to his employer from AbbVie, BMS, Pfizer, MSD, Roche and personal fees from AbbVie, BMS, Pfizer, MSD, Roche, Janssen, Novartis and UCB. Edward Vital has received research grants paid to his employer from AstraZeneca and Sandoz, and personal fees from Genentech, Aurinia, Lilly and Modus Therapeutics. Khaled Mahmoud, Ahmed Zayat, Yuzaiful Yusof, Katherine Dutton, Chee Seng Yee, Lee Suan Teh, Nora Ng, David D’Cruz and Elizabeth Hensor have no financial disclosures.
Data Availability
Please contact Dr Vital to discuss data availability requests
